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Aims and scope 
Ovarian cancer is one of the most frequent cause of females’ cancerrelated- deaths. 
Close to 239.000 new cases of ovarian cancer (OC) are diagnosed annually world-
wide and this malignancy carries a higher mortality rate (approximately 152.000 each 
year) than all other female genital cancers combined.  Striking geographical 
differences in its occurrence are noted. OC ranked 5th among the most common lethal 
cancers in the US in 2014, and its prevalence is known to be unusually high in Eastern- 
and Central Europe. According to the American Cancer Society in 2017 approximately 
22,440 women will be diagnosed with ovarian cancer, and 14,080 women will die of 
this disease. Epithelial ovarian cancer (EOC) accounts for 90% of all malignant ovarian 
tumours. The overall prognosis is poor, rate of remission sets only 40–50% of all cases  
 In advanced stages of epithelial ovarian cancers the 5 year survival rate is only about 
27%. According to Hungarian National Healthcare System data, in 2017, 15128 female 
were diagnosed with OC, ca. 1100 in ovarian cancer. 90% of ovarian cancers are 
epithelial. Cancer morbidity and mortality shows no diffence in regions of Hungary, 
neighter can observe better prognostic tendency in 5 year survival survival, which is 
observed in colorectal cancers.  
Primary debulking surgery and platinum-based chemotherapy are the dominant forms 
of current treatment options. Despite surgery and platinum-based systemic treatment 
the 5-year survival of these patients is dismal (cca27%). Although age, performance 
status, histology type, Inter-national Federation of Gynecology and Obstetrics (FIGO) 
stage and tumor grade are fundamental in determining prognosis of AEOC, there is 
undisputable need for identifying additional specificmolecular predictive parameters.  
Epithelial ovarian cancer (EOC) accounts for 90% of all malignant ovarian tumours. 
The overall prognosis is poor, rate of remission sets only around half of all cases. 
Ascites and peritoneal dissemination is a typical and prospective phenomenon is 
EOCs. Tumor cells detach from the primary neoplasms and easily survive whilst 
floating in ascites fluid and eventually anchor onto the visceral or parietal peritoneum. 
Selection of cancer cell subtypes, only those cells which are capable of avoiding 
detachment-induced anoikis will survive. This pathomechanism is thought to play 
important role by alterations of the entire adhesion molecule expression profile 
accompanied by disassembling junctional structures, re-organization of the 
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cytoskeleton plus re-emerging vimentin expression. The cumulative effects of these 
alterations are represented by increased motility and proliferation of the tumor cells, by 
their ability to avoid apoptosis and anoikis, and by the active secretion of matrix 
metalloproteases. By these surface related changes co-working with active 
signaltransduction, the tumor cells will be capable to reach other organs surfaces. This 
is called intraabdominal dissemination – the crutial point of EOC high mortality.  
It is a relevant clinical-onco-pathological expectation to find predictive and for a certain 
degree predictive factors to calculate proper treatment for early progressive tumors 
with and to determine medication for long term survival patients. The latest 
oncotherapeutic protocols require prognostic and predictive markers to have the ability 
to give more individualized and cost/benefit effective treatments and interventions.  
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Aims and scope 
 Our observations are oriented to test expressional profile changes of adhesional 
molecules and prognostic markers to find molecular predictors (as 
immunhistochemical markers) of early tumor progression and long term 
survival.  
 We intended to clarify whether the changes of expression patterns of cell 
membrane associated proteins (E-cadherin and β-catenin), Ki-67 proliferation 
index and p53 protein are showing differences in EOC’s peritoneal 
dissemination.  
 Our goal was to clarify differences in protein profiles of low-grade and high-
grade tumors in solid tumors and malignant effusion, as well.  
 We intended to test the applicability of cytological microarray (CMA) techniques 
in analyses of tumor progression and metastasis formation 
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Materials and methods 
Advanced epithelial ovarian cancer (AEOC) cases were collected from tissue archives 
of the Department of Pathology, ClinicalCentre, University of Debrecen, Department of 
Pathology, Albert Szent-Györgyi Health Centre, University of Szeged, Semmelweis 
Hospital of Kiskunhalas and Csongrád County Health Care Centre covering the time 
period of 16 years (1999–2015). The fundamental selection criterion was EOC in 
advanced clinical stage irrespective of pathological grading. Stages with spread 
beyond the ovaries were involved: FIGO Ic, FIGO IIc, FIGO IIIa, FIGO IIIb, FIGO IIIc, 
FIGO 4. 34 cases were FIGO stage III or IV, and 10 cases FIGO stage Ic, or IIc. All 
cases were selected on the basis of their original histopathology reports. Relevant 
clinical information was obtained from patients’ medical records using the appropriate 
electronic databases. The mean age was 63 years, all patients had AEOC without 
additional malignant conditions. Patients whose tumor progressed within twelve 
months following the introduction ofthe first platinum based therapeutical regimen were 
assigned “EP [early progressive] cases”. Patients surviving at least one hundred 
months after the primary diagnosis of AEOC comprised the LTS [long term survival] 
group. Almost all patients had primary platinum-based Taxol-Carboplatin (TC) therapy, 
or further variations of the following 3protocols: (i) conventional first line 
cyclophosphamide + cisplatin(CP); (ii) cyclophosphamide + doxorubicin + cisplatin 
(CAP) or(iii) cyclophosphamide + 4-epi-doxorubicin + cisplatin (CEP). Those patients 
who had received non-platinum- based primary chemotherapy were excluded. Lack of 
tumor samples, missing exact OS, incomplete follow up or suboptimal tissue sample 
(e.g.: only biopsy) were the most common causes for exclusion of patients. Thus, in 
the end, out of the primarily selected 431 cases, a total of 44 patients represented 
either “EP” or “LTS” categories, as defined above. 
The archives of the Department of Pathology at the University of Debrecen Clinical 
Center were searched for cases of malignant epithelial ovarian tumors for which tissue 
samples of the primary tumor or that of a peritoneal deposit (omentum, parietal pelvic 
peritoneum, abdominal viscera) together with cell blocks of tumorous ascites samples 
from the same patient were both available. A total of 27 patients met the inclusion 
criteria. These EOC cases were collected covering the time period of 5 years (2009–
2014). All histological sections were reviewed by two pathologists (LT and BN) for 
confirmation of the initial diagnoses.  
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New TMA blocks were built. A total of 237+318 cores were utilized all in all 5+7 TMA 
blocks from the selected 44+27 tumors. 
 
Tissue microarray (TMA) construction.  
All tumor samples were fixed in 4% buffered formalin and embedded in paraffin. All 
histological sections were reviewed by two pathologists (LT and BN) for confirmation 
of the initial diagnoses. Representative areas within the relevant paraffin blocks were 
identified by using the corresponding HE stained slides. From these areas 1 mm thick 
core samples were retrieved using a TMA master (3DHistech Budapest, Hungary) and 
positioned in the recipient paraffin array block. Three representative cores were 
obtained from each tumor. If for any reason one or more immunohisto-chemical 
reactions failed, or either the cores were lost or severely damaged, plus if the cores 
were non-representative (were necrotic or comprised of dominantly non-neoplastic 
tissue), new cores were punched from other areas of the original block(s) and a new 
TMA block was built. A total of 237 cores were utilized in 5 TMA blocks from the 
selected 44 tumors. 
Ascites samples were handled as follows. 50 ml a liquid of ascites fluid were fixed in 
10% buffered formalin for 12-24 hours at 4°C, followed by 10 min centrifugation at 2500 
rpm. The sediment was mixed into 3% agar gel at 56°C. After solidification at room 
temperature was complete, the cell-containing agar gel was transferred into routinely 
used tissue cassettes which allowed further fixation, dehydration and routine tissue 
processing. Only the “high enough cellularity” samples (high tumour cell density HTCD 
group N = 22) were used to obtain 2 mm thick cores (3 cores from each) which were 
adequate for CMA block construction using again the TMA master (3DHistech 
Budapest, Hungary). The remaining 5 low cellularity samples (low tumour cell density 
(LTCD) group) were used for IHC analysis as conventional “whole-surface” sections. 
Four micron thick sections from the TMA blocks were used forIHC. The slides were 
deparaffinised and rehydrated following the routine protocols supplied with the 
antibodies. Endogenous per-oxidase activity was blocked with 0.5% H2O2 for 30 min. 
Antigen retrieval was accomplished in 10 mM citrate buffer (pH 6.0) in a microwave at 
600 W for 5 min. Nonspecific binding was blockedwith 1% BSA for 10 min. 
8 
 
Subsequently, the slides were incubated with the primary antibody: β-catenin 
(Transduction Laboratories,Lexington KY) clone C19220, 1:100, E-cadherin 
(Transduction Lab-oratories, Lexington KY) clone 36, 1:100, MIB-1 (Ki-67) 
(Dako,Glostrup, Denmark) clone, 1:100 and p53 (Labvision, Fremont, CA)clone, 1:100 
for 30–60 min, at 37◦C. The slides were incubated with biotinylated rabbit anti-mouse 
immunoglobulin as the second anti-body and were subsequently treated with 
streptavidin-peroxidase conjugate for 30 min at 37◦C temperature. DAB was used as 
chromogen substrate. After counterstaining with haematoxylin, the slides were 
dehydrated and mounted. Slides without the primary antibody were used as negative 
controls. 
IHC reactions were recorded and digitalized by Mirax slidescanner. Evaluation of slides 
were made on digitalized slides. LTCD groups’ slides were evaluated in usual analogue 
system. 
Evaluation 
Survival cases: Membranous and nuclear β-catenin expression (IHC “decoration”) was 
evaluated separately. Those cases in which only <10% “decorated” (‘stained’, i.e., 
positive) cells were observed were classified as negative. If the decorated cells’ 
number was >10% of all cells, the sample scored positive. Only membranous E-
cadherin IHC-reaction was regarded as relevant and those cases scored pos-itive in 
which the decorated cells’ number exceeded 10% of all the cells. The 10% cut-off value 
was applied for Ki-67 and p53 nuclear reactivity as well. 
Solid tumor vs. ascites cases: Nuclear and cell membrane decoration for β-catenin 
were assessed separately. For E-cadherin only membrane-localized decoration was 
valued as positive, while for p53 and Ki-67 only nuclear reactivity meant a positive 
score. In each positive case the actual percentage of positively decorated tumor cells 
was determined. We determined the range of IHC positivity, and used no cut-off values.  
Statistical analysis:  
Differences involving classical and molecular features betweenthe LTS and EP groups 
were analyzed with Kaplan–Meier test torecognize statistical significance. Multivariate 
logistic regression analysis helped to detect independent factor(s) that might 
haveinfluenced clinical outcome, namely long-term OS and/or PFS. 
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The IBM SPSS 24 software (specifically Mann-Whitney-Wilcoxon test) was utilized for 
comparative evaluation of the results which have been collected from primary tumors 
and ascites samples, and also Spearman correlations were calculated.   
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Results 
Accordig to prognostic study the median age of patients which was 63 years (95% CI; 
52.1–57.4). The majority of the tumors were serous carcinomas (70.5%). Other 
histological types were endometrioid (6.8%), mucinous (9.1%), and dedifferentiated 
carcinomas (13.6%). Further special histotypes (E.g., clear cell carcinoma or malignant 
Bernner-tumour) were not encountered. Twenty-two patients (50%) had optimal tumor 
debulking surgery representing the most effective tumor volume reduction. The 
majority (72.7%) of carcinomas was in FIGO stage III. FIGO stage I and II C comprised 
18.2%, and 4.5%, respectively. Within the group of FIGO stage III, stage IIIC 
dominated (61.3%), while FIGO stage IIIA and IIIB were represented by 2.3% and 
9.1%, respectively. Only 4.5% of all tumors comprised the FIGO stage IV group. 
Histological grade I and grade II tumors were collectively grouped (total number 23) as 
“low-grade tumors” (52.3%). The number of grade III lesions was 21, which were 
classified as high-grade tumors” (47.7%). We identified 14 patients (32%) with early 
progression (EP) and 17 patients (39%) belonged to long term survivors (LTS). 
IHC results 
P53: Detection of p53 reactivity. In low-grade [LG] tumors nuclear expression of p53 
was found in 11/23 (47.8%). The same reaction was positive in 14/21 (66.7%) in high-
grade [HG] carcinomas. In the samples from optimal tumor debulking 10/22 (45.4%) 
showed p53 nuclear expression, while in cases of suboptimal debulking 15 cases 
(68.1%) had p53 expression. In serous tumors p53 nuclear expression was detected 
in 18 cases (58%), in non-serous phenotypes 7 cases (53%) proved positive with this 
antibody. In patients older than 65 years 65% (13 patients) expressed nuclear p53, 
while in those below the age of 65 years, nuclear expression of p53 was detected in 
50% (12 patients).  
Ki-67: The Ki-67 proliferation marker was expressed in 10/23 cases (43%) in LG 
tumors and 14/21 (66.7%) in HG tumors. In 9 samples (40.9%) showed Ki-67 nuclear 
expression from optimal tumor debulking, while 15 cases (68.1%) from suboptimal 
debulking specimens displayed Ki-67 expression. In serous tumors Ki-67 nuclear 
expression was detected in 17 cases (54.8%), in non-serous phenotypes 7 cases 
(53.8%) were positive. In patients over 65 years thirteen cases (43.3%) expressed 
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nuclear Ki-67, while the younger patient group 11 cases (45.8%) showed specific 
nuclear Ki-67 decoration.  
E-cadherin: Membranous E-cadherin reactivity. In LG tumors we found expression of 
E-cadherin in 17 cases (73.9%), while 14 cases (80.9%) were positive from the HG 
tumor group. From the optimal tumor debulking series 16 samples (72.7%) showed E-
cadherin expression, while this result was positive in 18 cases (81.8%) from the 
suboptimal debulking specimens. In serous tumors E-cadherin expression was 
detected in 25 cases (80.6%), in non-serous phenotypes 9 cases (69.2%) presented 
the same result. In patients over 65 years of age 17 cases (85.0%) expressed 
membranous E-cadherin, while in individuals below age 65, membranous expression 
of E-cadherin was detected in 17 cases (70.8%). 
β-catenin: Membranous β-catenin decoration. In LG tumors we found membranous 
expression of -catenin in 18/23 cases (78.2%), and 15/21 patients’ samples (71.4%) 
from the HG group displayed the same positivity. In cases of optimal tumor debulking 
17/22 samples (77.2%) showed -catenin membranous expression, while this result 
was observed in 16 cases (72.7%) of suboptimal debulking series. In serous tumors β-
catenin membranous expression was detected in 25 cases (80.6%), in non-serous 
phenotypes 8 cases (61.5%) showed this IHC pattern. In patients over 65 years 14 
cases (70.0%) expressed membranous β-catenin, while in 19 cases (79.1%) from 
younger individuals was membranous expression of β-catenin detected. Nuclear β-
catenin IHC positivity. In LG tumors we found nuclear expression of β-catenin in 3/23 
cases (13.0%), and in HG tumors 3/21 (14.2%) tumors showed this decoration. In 
cases of optimal tumor debulking 4/22 samples (18.2%) showed nuclear β-catenin 
reactivity, while from the series of suboptimal debulking 2 cases (9.1%) nuclear 
positivity indicated β-catenin transposition. In serous tumors β-catenin nuclear 
expression was detected in 1 cases (3.2%), in non-serous phenotypes 5 cases (38.4%) 
were similarly decorated. In patients, over 65 years 4 cases (20.0%) expressed -
catenin in the cell nuclei, while in younger individuals nuclear β-catenin expression was 
detected in 2 cases (8.3%).  
β-catenin: Nuclear β-catenin expression was detected in a total of 6 (13.6%) of all 
cases. In all of them nuclear positivity was accompanied by synchronous membranous 
β-catenin reactivity. Solely membranous β-catenin expression was detectable in 33 
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(75%) of all cases. E-cadherin expression was positive in 34 patients (77.2%). High Ki-
67 labeling index was detected in 24 cases (54.5%) and p53 nuclear positivity was 
observed in 25 cases (56.8%).  
Comparison of the putative impact of the features characterizedby IHC as well as that 
of the clinical parameters on OS and PFS of the EP and LTS patients was evaluated 
applying univariate and multivariate statistical analyses.  
OS: Univariate analysis indicated that serous histological type has a potentially 
negative impact on outcome when compared to different histological categories (68.03 
mo. vs. 117.01 mo.;p = 0.025). Similar conclusion was reached with regard to 
suboptimal debulking, that resulted in significantly shorter OS (57.48 mo.vs 105.36 
mo.; p = 0.003) both with univariate- and with multivari-ate (0.325; p = 0.005) analysis. 
There was no statistically significant association between OS and age-, tumor grade- 
or tumor stage.Nuclear β-catenin expression was only detected in LTS patient’s group 
(146,67 mo. vs. 71,84 mo;p=0.041) while this reaction was negative in the EP 
patient’sgroup (0/27). Positivity of the p53 IHCreaction did show an impact on OS when 
compared to p53 negative cases (70.40 mo. vs. 99.80 mo.), however, this difference 
was not statistically significant (p = 0.057). None of the other parameters, namely, 
membranous β-catenin staining, E-cadherin- or Ki-67expression appeared to have 
significant prognostic value  
PFS: As expected if tumor debulking is suboptimal (i.e., thereis residual tumor mass) 
that has a significant negative impacton PFS compared to radical tumor removal (14.00 
mo vs. 42.93mo. respectively; p=0.001) both with univariate analysis and with 
multivariate analysis (0,329; p=0.002). No statistically significant correlation between 
PFS/age, PFS/histopathological cell type,PFS/tumor grade- or tumor stage was found. 
Patients with high Ki-67 index had shorter PFS than those patients with low KI-67 (26 
mo. vs. 61.95 mo.; p= 0.039) with univariate analysis. It is of note that despite of early 
progression, adequate response to platinum based therapy was observed in 3 cases 
which resultedin favorable lengthening of OS to more than 100 months.In 3 of the 6 
cases characterized by nuclear β-catenin expression we observed relapse of the 
disease over 12 months. One of these patients had suboptimal primary tumor 
debulking. In these cases platinum re-induction therapy was performed with success 
– the patient OS attained our limit. 
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Results of observations: malignant effisions and solid tumors.  
Accordig to our solid tumor and ascites study the total number of cases included in the 
study was 27, out of these 78% (21) represented primary OC, and the remaining 
samples had been removed from metastatic foci localized on peritoneal surfaces of the 
omentum, abdominal viscera or pelvic wall. Tumors had been graded prior to the study-
selection: 75% (18) tumors were high grade [HG] and 25% (9) were low grade [LG] 
neoplasms. The higher stages (FIGO II-IV) were lumped together as group 
representing peritoneal dissemination. CMA blocks were constructed from 22 ascites 
samples with high cellularity (HCTD group) and from five samples with low cellularity 
traditional sections were used for immunohistochemistry (IHC). The results of IHC 
reactions were evaluated by digital image analysis.  
IHC results from solid tumors 
p53 protein expression as shown by IHC positivity was rather variable: range 0-100%, 
mean: 45.56%. Ki-67 positivity also covered a broad range (1-68%), mean: 19.08%. 
E-cadherin IHC positivity varied between 0-91% (mean: 31.4%), while membranous β-
catenin expression occurred in 40-100% (mean: 82.19%) without any case of nuclear 
expression thereof.  
IHC reactivity profile of ascitic tumor cells  
The range of p53 positivity was similar to that of solid tumors (0-100%), however the 
mean value in the ascites series was considerably lower: 32.76%. Results of the Ki-67 
IHC reaction on ascitic cells also differed from that of solid tumors and varied between 
1-83% (mean: 25.72%). In the ascetic samples E-cadherin expression was detectable 
in a diversified representation (0-92%), mean: 39.52%. Nuclear β-catenin positivity was 
not observed in this series either, whilst the mean value for membranous decoration 
was 58.77%, covering a range of 0-100%.  
Significantly higher number of p53 positive cells were detected in primary tumors than 
in ascitic cells (45.56 vs 32.76, p=0.001). Although on average the proliferation marker 
Ki-67 decorated more ascitic cells than cells in solid tumors, this difference was not 
statistically significant. (25.72% vs. 19.08%, p=0.101). E-cadherin expression was 
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more abundant in ascitic cells than in primary tumor cells, however, this difference was 
not significant, either. (39.52% vs. 31.40%, p=0.294). Ascitic tumor cells’ membranous 
β-catenin expression was significantly lower than that of cells from primary tumors. 
(82.19 vs 58.77% p=0.006).  
To test the hypothesis that grade and stage is influenced by the level of expression of 
the IHC markers analyzed we set out to compare IHC results as a function of these 
variables. Histopathological grade LG primary tumors’ cells average p53 expression 
was 24.89%, while in HG tumors this value was 58.06%, this difference was statistically 
significant (p=0,039). Similarly significant (p=0,004) difference characterized Ki-67 
decoration that occurred in only 6.22% of LG primary tumors, but was seen in 25.11% 
of HG neoplasms. E-cadherin was detectable in 33.75% in LG tumors and this value 
was not markedly different from the 30.44% labelling observed in HG tumors. β-catenin 
expression was seen in 78.67% of LG tumorous cells, also quite similar to the value 
detected in HG tumors (81.89%). Expression profiles of the 4 markers in ascitic cells 
were not significantly coupled with grades, although the tendencies of differences (i. 
e., lower p53, higher Ki-67 expression as well as increased E-cadherin and decreased 
β-catenin expression in ascitic cells compared to primary tumors) which characterized 
the lumped data prevailed in both high and low grade samples. Correlations between 
tumor stage and IHC marker-expression E-cadherin expression was lower (27.45%) in 
more widespread tumors (advanced stages) than in rather confined tumors (44.83 % 
in early stages), although the difference was statistically not significant. Likewise, the 
value portraying membranous β-catenin expression in early stage-cases (86%) was 
not significantly higher than that observed in more advanced tumors (79.33%). There 
seems to be an elevated p53 and Ki-67 expression in more advanced cases but 
interpretation of these observations deserve caution due to small sample numbers and 
also because more advanced tumors tend to be of higher grades.  
Comparisons between cells from primary, metastatic and ascitic tumor cells 
Expression of p53 protein increased, although not significantly in metastatic tumors 
when compared to those from primary tumors (66.3% vs 41.47%). Non-significant 
decrease of the Ki-67 labeling index (LI=16%) was detected in metastatic neoplastic 
foci when contrasted with LI determined in primary tumors (LI=19.61%). E-cadherin 
expression levels were moderately lower (28.6%) in metastatic cell populations than 
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those in primary tumors (32.14%). This difference was rather augmented when 
comparisons were made within the early stage tumor group, while the variance turns 
non-significant in advanced stages (44.8%, 27.06% vs. 28.6%). The IHC scores that 
indicate β-catenin expression decrease from 82% (primary) to 76.67% (metastatic) and 
this decline is consistent irrespective of tumor stage. Ascitic cells express less mutant 
p53 protein compared to cells from primary tumors (28.95% vs 41.48%), the same 
reduction is detectable when comparing ascitic cells to cells from metastatic foci (48% 
vs 66.33%). Note that these differences are statistically not significant. There is a 
synchronous increase in proliferative activity in ascitic cells which is indicated by the 
augmented Ki-67 LI values (primary tumor vs. ascetic tumor cells, 19.62 vs. 25.65%; 
metastasis vs. ascetic tumor cells, 16.0% vs. 26.0%, respectively. Ascitic cells express 
more E-cadherin than primary tumor cells (42.1% vs 32.14%) and less β-catenin: 
55.19% in ascitic cells and 82% in primary tumor cells. Adhesion molecules’ expression 
values (% of labelled cells) of metastatic tumor cells and of ascitic tumor cells were 
almost identical, the differences were within observational error limits. For E-cadherin 
the values were 28.6% (metastatic) and 26.5% (ascitic); for β-catenin 76.67% 
(metastatic) and 73.8% (ascitic).  
Result summary 
Solid tumors and ascites cells p53 and Ki-67 expression showed correlation with tumor 
grade. P53 and Ki-67 expression elevated in high-grade primary tumor cells and 
ascites cells. Slightly decreased E-cadherin and moderately elevated β-catenin 
expression was detected in high-grade tumors. Ascites tumor cell E-cadherin 
expression elevated and membranous β-catenin expression decreased in both low-
grade and high-grade cases compared to that in primary tumors. Expression of E-
cadherin in ascites intensifies, that is specific to ovarian cancer cells. Meanwhile β-
catenin membranous expression shows marked decrease. Expressional profile of 
metastatic tumours and ascites tumour cells presented similar level of decrease and 
ascites tumour cells had significantly lower p53 and elevated Ki-67 expressional 
activity.  
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Concusions of the study 
 Nuclear β-catenin is a predictive marker of long term survival and for a certain 
degree predicts platinum sensitivity  
 Proliferation marker Ki-67 is an unfavorable predictor of early progression 
 Cell adhesional molecule E-cadherin has no effect on OS or PFS - according to 
our study – but plays important role in ascites transmitted intraabdominal tumor 
progression with intensifying membranous expression in ascites  
 Cell membrane associated β-catenin protein expression decreases in malignant 
intraabdominal effusion, particularly in tumors with early stage 
 Elevated protein p53 expression is tipical in high-grade solid EOCs and 
malignant peritoneal effusion, as well 
 Ki-67 nuclear expression intensified in ascitic tumor cells compared to solid 
tumors 
 Cytology microarray is exclusively suitable method to compare malignant 
effusions with solid tumors.  
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